Abstract: A capacitor circuit (capacitor device 20, 30, 34, 50) in which a plurality of capacitors (41 to 45) are connected to each other is included, one or two or more capacitors (overvoltage short-circuiting capacitors 40, 40a, 40b, 40c, 40d) in the capacitor circuit have a dielectric breakdown voltage made lower than that of another capacitor, and the one or two or more capacitors having the lower dielectric breakdown voltage are subjected to dielectric breakdown due to application of an overvoltage earlier than the other capacitor so that the capacitor circuit is short-circuited. As a result, the safety of the capacitor device and a device connected thereto can be enhanced.

Abstract: A capacitor circuit (capacitor device 20, 30, 34, 50) in which a plurality of capacitors (41 to 45) are connected to each other is included, one or two or more capacitors (overvoltage short-circuiting capacitors 40, 40a, 40b, 40c, 40d) in the capacitor circuit have a dielectric breakdown voltage made lower than that of another capacitor, and the one or two or more capacitors having the lower dielectric breakdown voltage are subjected to dielectric breakdown due to application of an overvoltage earlier than the other capacitor so that the capacitor circuit is short-circuited. As a result, the safety of the capacitor device and a device connected thereto can be enhanced.

Abstract: Compounds of formula (I): in which the variables are defined herein, are useful for the treatment of cancer in patients which express the EGFR T790M mutation.

Abstract: [Problem] A compound which is useful as an inhibitor on EGFR T790M mutation kinase activity is provided. [Means for Solution] The present inventors have investigated a compound having an inhibitory action on an EGFR T790M mutation kinase, and have found that a pyrazinecarboxamide compound has an inhibitory action on an EGFR T790M mutation kinase, thereby completing the present invention.

Abstract: A spring seat is mounted to a suspension arm to receive a coil spring of a suspension, a spring seat body is provided with a receiving part for receiving the coil spring and a locking protrusion, which projects from the spring seat body to the side opposite to the receiving part so as to be locked in a locking hole formed in the suspension arm, are formed integrally using an elastic member, and a core material harder than the elastic member is incorporated in the spring seat body and the locking protrusion.

Abstract: As a result of extensive studies on NAD(P)H oxidase inhibitors, the present inventors found that a quinolone derivative having, at the 2-position, an alkyl group substituted with a heteroatom or the like has an excellent NAD(P)H oxidase inhibitory activity, and accomplished the present invention. The compound of the present invention has a reactive oxygen species production inhibitory activity based on the NAD(P)H oxidase inhibitory activity, and therefore can be used as an agent for preventing and/or treating diabetes, impaired glucose tolerance, hyperlipidemia, fatty liver, diabetic complications and the like.

Abstract: A trailing arm type suspension improves the handling (driving stability) and the response (driving response) of an automobile by increasing the installation rigidity of a suspension member to a vehicle body frame. In the trailing arm type suspension including a pair of right and left trailing arms which extend in the vehicle longitudinal direction, a reinforcing bar for connecting a suspension member in the vehicle rear side of the trailing arm to a connecting part of a vehicle body frame in the vehicle front side of the suspension member, is disposed between a fuel tank and the trailing arm, and the reinforcing bar and the trailing arm overlap each other as viewed from the side of the vehicle.

Abstract: A reactor includes a ringed core and a magnetic excitation coil. The ringed core includes a plurality of core blocks made of a magnetic material which are connected in a ring through gaps. The magnetic excitation coil is wound around the ringed core. The ringed core has a magnetic leg region around which the magnetic excitation coil is wound and a yoke portion region where the magnetic excitation coil is not wound. A length of the gap in the magnetic leg region is smaller than a length of the gap in the yoke portion region. Positions of gaps or magnetic excitation coil may be modified. A power converter using the reactor is also disclosed.

Abstract: A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.

Abstract: To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with ?-form crystal and ?-form crystal of (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide. The ?-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The ?-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the ?-form crystal.

Abstract: The present invention provides a condensed pyrimidine compound represented by formula (I) or pharmaceutically acceptable salt thereof: where A represents a ring where at least one carbon atom within said ring is optionally substituted with one or more groups selected from the group consisting of lower alkyl, —O-(lower alkyl), halogen atom, carboxyl, —CO2-(lower alkyl), and carbamoyl, R1 represents: (1) phenyl substituted with at least three halogen atoms, which may have at least one additional substituent, or (2) cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, or cycloheptyl, each of which is optionally substituted; and R2 represents a group represented by formula (II) or an optionally substituted cyclic amino: wherein R21 and R22 may be identical or different and each represents —H, lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, phenyl, heteroaryl, non-aromatic heterocyclyl, or —O-(lower alkyl), each of which is optionally substituted.

Abstract: As a result of extensive studies on NAD(P)H oxidase inhibitors, the present inventors found that a quinolone derivative having, at the 2-position, an alkyl group substituted with a heteroatom or the like has an excellent NAD(P)H oxidase inhibitory activity, and accomplished the present invention. The compound of the present invention has a reactive oxygen species production inhibitory activity based on the NAD(P)H oxidase inhibitory activity, and therefore can be used as an agent for preventing and/or treating diabetes, impaired glucose tolerance, hyperlipidemia, fatty liver, diabetic complications and the like.

Abstract: A trailing arm type suspension improves the handling (driving stability) and the response (driving response) of an automobile by increasing the installation rigidity of a suspension member to a vehicle body frame. In the trailing arm type suspension including a pair of right and left trailing arms which extend in the vehicle longitudinal direction, a reinforcing bar for connecting a suspension member in the vehicle rear side of the trailing arm to a connecting part of a vehicle body frame in the vehicle front side of the suspension member, is disposed between a fuel tank and the trailing arm, and the reinforcing bar and the trailing arm overlap each other as viewed from the side of the vehicle.

Abstract: A spring seat is mounted to a suspension arm to receive a coil spring of a suspension, a spring seat body is provided with a receiving part for receiving the coil spring and a locking protrusion, which projects from the spring seat body to the side opposite to the receiving part so as to be locked in a locking hole formed in the suspension arm, are formed integrally using an elastic member, and a core material harder than the elastic member is incorporated in the spring seat body and the locking protrusion.

Abstract: There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

Abstract: A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.

Abstract: To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with ?-form crystal and ?-form crystal of (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetanilide. The ?-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The ?-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the ?-form crystal.

Abstract: There are provided new pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety, and the like or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.

Abstract: To provide novel crystals useful as an ingredient for the production of a diabetes remedy. The invention is concerned with ?-form crystal and ?-form crystal of (R)-2-(2-aminothiazol-4-yl)-4?-[2-[(2-hydroxy-2-phenyleth-yl)amino]ethyl]acetanilide. The ?-form crystal does not exhibit hygroscopicity and has stability such that it can be used as a medicine, and is useful for mass synthesis in the industrial production. The ?-form crystal does not relatively exhibit hygroscopicity and is also useful as a production intermediate of the ?-form crystal.

Abstract: There are provided novel pyrimidine derivatives which has been fused with an aromatic heterocycle selected from thiophene, thiazole and pyridine or pharmaceutically acceptable salts thereof; and a pharmaceutical composition comprising said compound as an active ingredient. These compounds exhibit excellent promoting activity on insulin secretion and activity against hyperglycemia. Hence, the pharmaceutical compositions comprising such compounds as active ingredients, based on these actions, are useful for treating and/or preventing insulin-dependent diabetes (type 1 diabetes), non-insulin-dependent diabetes (type 2 diabetes), insulin-resistant diseases, obesity, and the like.